122 related articles for article (PubMed ID: 37548052)
21. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
[TBL] [Abstract][Full Text] [Related]
22. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
Fetterly GJ; Owen JS; Stuyckens K; Passarell JA; Zannikos P; Soto-Matos A; Izquierdo MA; Perez-Ruixo JJ
Cancer Chemother Pharmacol; 2008 Jun; 62(1):135-47. PubMed ID: 17922277
[TBL] [Abstract][Full Text] [Related]
23. Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.
Rühs H; Becker A; Drescher A; Panetta JC; Pui CH; Relling MV; Jaehde U
PLoS One; 2012; 7(9):e46015. PubMed ID: 23049924
[TBL] [Abstract][Full Text] [Related]
24. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice.
Karlsson Sundbaum J; Eriksson N; Hallberg P; Lehto N; Wadelius M; Baecklund E
Int J Rheum Dis; 2019 Jul; 22(7):1226-1232. PubMed ID: 31012257
[TBL] [Abstract][Full Text] [Related]
27. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
28. "Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?".
García DS; Saturansky EI; Poncino D; Martínez-Artola Y; Rosenberg S; Abritta G; Ascimani-Peña C; Cravero A
Ann Hepatol; 2019; 18(5):765-769. PubMed ID: 31105018
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of apigenin on altered lipid peroxidation, inflammation, and antioxidant factors in methotrexate-induced hepatotoxicity.
Goudarzi M; Kalantar M; Sadeghi E; Karamallah MH; Kalantar H
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):523-531. PubMed ID: 33057777
[TBL] [Abstract][Full Text] [Related]
30. Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses.
Ghoneum M; El-Gerbed MSA
Cancer Chemother Pharmacol; 2021 Dec; 88(6):961-971. PubMed ID: 34505929
[TBL] [Abstract][Full Text] [Related]
31. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
32. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
33. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetic Model of Methotrexate in Brazilian Pediatric Patients with Acute Lymphoblastic Leukemia.
de Oliveira Henz P; Pinhatti AV; Gregianin LJ; Martins M; Curra M; de Araújo BV; Dalla Costa T
Pharm Res; 2023 Jul; 40(7):1777-1787. PubMed ID: 37291462
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
36. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
37. Understanding hemoglobin contribution to high-dose methotrexate disposition-population pharmacokinetics in pediatric patients with hematological malignancies.
Škorić B; Jovanović M; Kuzmanović M; Miljković B; Vučićević K
Eur J Clin Pharmacol; 2024 May; 80(5):697-705. PubMed ID: 38347227
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
[TBL] [Abstract][Full Text] [Related]
39. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood.
Weber BL; Tanyer G; Poplack DG; Reaman GH; Feusner JH; Miser JS; Bleyer WA
NCI Monogr; 1987; (5):207-12. PubMed ID: 3481038
[TBL] [Abstract][Full Text] [Related]
40. Melatonin protects against methotrexate hepatotoxicity in young rats: Impact of PI3K/Akt/mTOR signaling.
Wang SC; Huang YC; Hsiao CC; Sheen JM; Huang LT; Lo WS; Hsieh HY; Chen YC
J Biochem Mol Toxicol; 2023 May; 37(5):e23323. PubMed ID: 36890697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]